Investors purchased shares of Eli Lilly and Co. (NYSE:LLY) on weakness during trading on Friday. $122.40 million flowed into the stock on the tick-up and $52.04 million flowed out of the stock on the tick-down, for a money net flow of $70.36 million into the stock. Of all stocks tracked, Eli Lilly and had the 19th highest net in-flow for the day. Eli Lilly and traded down ($0.37) for the day and closed at $80.22

A number of analysts recently commented on LLY shares. TheStreet raised shares of Eli Lilly and from a “hold” rating to a “buy” rating in a report on Friday, May 27th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Thursday, May 26th. Jefferies Group reaffirmed a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and in a report on Friday, May 13th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a report on Tuesday, March 29th. Finally, Deutsche Bank AG reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Sunday, March 27th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $95.10.

The firm’s 50-day moving average is $76.15 and its 200 day moving average is $75.99. The stock has a market capitalization of $85.03 billion and a price-to-earnings ratio of 36.97.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, April 26th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.85 by $0.02. The business had revenue of $4.87 billion for the quarter, compared to the consensus estimate of $4.82 billion. During the same period last year, the firm posted $0.87 EPS. Eli Lilly and’s revenue for the quarter was up 4.7% on a year-over-year basis. Analysts anticipate that Eli Lilly and Co. will post $3.57 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 9th. Investors of record on Monday, August 15th will be issued a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend is Thursday, August 11th.

In related news, SVP Alfonso G. Zulueta sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 27th. The shares were sold at an average price of $76.27, for a total transaction of $915,240.00. Following the completion of the sale, the senior vice president now directly owns 45,101 shares in the company, valued at $3,439,853.27. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Melissa S. Barnes sold 992 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $73.77, for a total transaction of $73,179.84. Following the sale, the senior vice president now owns 10,710 shares of the company’s stock, valued at $790,076.70. The disclosure for this sale can be found here.

Several hedge funds recently bought and sold shares of LLY. Gabelli Securities Inc. bought a new stake in Eli Lilly and during the fourth quarter valued at approximately $1,095,000. Hodges Capital Management Inc. boosted its stake in Eli Lilly and by 121.8% in the fourth quarter. Hodges Capital Management Inc. now owns 13,537 shares of the company’s stock valued at $1,141,000 after buying an additional 7,434 shares in the last quarter. TCI Wealth Advisors Inc. boosted its stake in Eli Lilly and by 0.5% in the fourth quarter. TCI Wealth Advisors Inc. now owns 14,349 shares of the company’s stock valued at $1,209,000 after buying an additional 76 shares in the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Eli Lilly and by 7.4% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 15,280 shares of the company’s stock valued at $1,287,000 after buying an additional 1,050 shares in the last quarter. Finally, Wellington Shields Capital Management LLC boosted its stake in Eli Lilly and by 1.8% in the fourth quarter. Wellington Shields Capital Management LLC now owns 15,732 shares of the company’s stock valued at $1,326,000 after buying an additional 273 shares in the last quarter.

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.